BGNE240517C220000
- 4.50
- 0.000.00%
BeiGene Newsroom
An Intrinsic Calculation For BeiGene, Ltd. (NASDAQ:BGNE) Suggests It's 47% Undervalued
Key Insights The projected fair value for BeiGene is US$317 based on 2 Stage Free Cash Flow to Equity Current share price of US$167 suggests BeiGene is potentially 47% undervalued Analyst price t
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
Glenmark Specialty, a subsidiary of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), will market Beigene's (SHA: 688235, HKG:6160) oncology medicines, Tislelizumab and Zanubrutinib, in India, acco
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
BeiGene, Ltd. BGNE is a next-gen oncology company focusing on discovering and developing innovative and affordable treatments for cancer patients worldwide.
Clinical research tool book “Everything is Visible” officially published and sold
BEIJING, May 20, 2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology treatment innovation company, today announced that “Everything Visible: Ten Scenarios for Visualization Applications in Clinical Research and Development” (hereinafter referred to as “Everything Visible”), which it co-organized with the Drug Information Association (DIA) China Digital Health Community (DHC)), has officially launched. “Everything is Visible” book cover “Everything Visible” is a systematic introduction to how data visualization can be applied to clinical medical research
[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow
Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.
Top Gap Ups and Downs on Thursday: WMT, TM, MUFG and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
BeiGene (06160) grants share options to subscribe for a total of 12,000 American Depositary Shares under the 2016 Options and Incentive Plan
BeiGene (06160) issued an announcement. On May 10, 2024, the Remuneration Committee of the Board of Directors was based on 201...
BeiGene (06160.HK): Grant of share options and restricted share units
Glonghui, May 16, 丨 BeiGene (06160.HK) issued an announcement. On May 10, 2024, the Board's Remuneration Committee granted 4 grantees the right to subscribe for a total of 11,800 American Depositary Shares and granted restricted share units involving a total of 7027 million American Depositary Shares to 164 grantees in accordance with the terms of the 2016 Options and Incentive Plan.
BeiGene Performance Analysis: A Hold Rating With Cautious Optimism Amidst Competitive Pressures
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
Study evaluating BRUKINSA in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentationBCL2 inhibitor sonrotoclax subject of multiple presentations h
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
BeiGene (688235.SH): Revenue exceeded 5 billion yuan in the first quarter, accelerating differentiated innovation
On May 8, BeiGene (688235)'s US stock performance report for the 2024 Q1 quarter and the A-share performance report were freshly released. Financial reports show that during the reporting period, BeiGene's total revenue reached 5.359 billion yuan, up 74.8% year on year; thanks to the rapid release of the two core self-developed products, the company's global product revenue reached 5.325 billion yuan, up 89.6% year on year and 17.8% month on month, exceeding market expectations. At the same time as revenue increased dramatically, thanks to strict expense management, BeiGene's operating expenses grew slowly. Current sales and management expenses accounted for 8 percent of product revenue compared to the same period last year
BeiGene Shenzhou Co., Ltd. 2024 First Quarter Report
BeiGene (688235.SH)'s first quarter revenue surged 74.8% to 5.359 billion yuan, R&D investment increased 18.1% to 3.328 billion yuan
BeiGene (688235.SH) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating
Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Is Maintained at Buy by TD Cowen
Express News | TD Cowen Maintains Buy on BeiGene, Raises Price Target to $254
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 51.35% TD Cowen $236 → $254 Maintains Buy 04/24/2024 40.62% TD Cowen $235 → $236 Maintains Buy
New Risks Emerge for BeiGene: Investors Alerted to Material Updates in Financial Disclosures